Neoplasm Staging

"Neoplasm Staging" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.

Descriptor ID	D009367
MeSH Number(s)	E01.789.625
Concept/Terms	Neoplasm Staging Neoplasm Staging Staging, Neoplasm Tumor Staging Staging, Tumor Cancer Staging Staging, Cancer TNM Staging TNM Staging Staging, TNM TNM Staging System Staging System, TNM Staging Systems, TNM System, TNM Staging Systems, TNM Staging TNM Staging Systems TNM Classification Classification, TNM Classifications, TNM TNM Classifications

Below are MeSH descriptors whose meaning is more general than "Neoplasm Staging".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Diagnosis [E01]
Prognosis [E01.789]
Neoplasm Staging [E01.789.625]

Below are MeSH descriptors whose meaning is related to "Neoplasm Staging".

Below are MeSH descriptors whose meaning is more specific than "Neoplasm Staging".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neoplasm Staging" by people in this website by year, and whether "Neoplasm Staging" was a major or minor topic of these publications.

Bar chart showing 410 publications over 31 distinct years, with a maximum of 31 publications in 2013 and 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	3	3
1996	0	5	5
1997	0	1	1
1998	0	3	3
1999	0	1	1
2000	1	3	4
2001	0	1	1
2002	2	3	5
2003	0	5	5
2004	1	11	12
2005	1	11	12
2006	0	9	9
2007	1	13	14
2008	0	23	23
2009	0	19	19
2010	2	21	23
2011	1	25	26
2012	1	16	17
2013	1	30	31
2014	1	30	31
2015	2	18	20
2016	3	12	15
2017	2	21	23
2018	1	25	26
2019	0	21	21
2020	1	17	18
2021	0	14	14
2022	0	7	7
2023	0	7	7
2024	0	10	10
2025	0	4	4

Below are the most recent publications written about "Neoplasm Staging" by people in Profiles.

Guo SS, Li XY, Liu LT, Jia GD, Liu SL, Sun XS, Luo DH, Yang JH, Xie SY, Li YF, Lv X, Xiang YQ, Xia WX, Sun R, Liu Q, Li JB, Wang P, Yang Q, Wang L, Wen DX, Jin J, Lin JY, Mo HY, Guo L, Zhao C, Guo X, Chen QY, Tang LQ, Mai HQ. Induction vs Adjuvant Chemoradiotherapy in Patients With High-Risk N2 to N3 Nasopharyngeal Carcinoma: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2025 Aug 01; 11(8):864-873.

View in: PubMed
Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva B, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Pr?sper F, Munshi NC. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025 Aug 20; 43(24):2739-2751.

View in: PubMed
Mita MM, Mita AC, Carver BJ, Shanahan JM, Mayes BA, Dufour PJ, Browning D, Anderson-Villaluz A, Petersen JS, Turnquist DJ, Cornelius P. A Phase 1 Safety Study of Evexomostat (SDX-7320) in Patients with Late-Stage Cancer: An Antiangiogenic, Insulin-Sensitizing Drug Conjugate Targeting METAP2. Cancer Res Commun. 2025 Jun 01; 5(6):1008-1017.

View in: PubMed
Moncayo AK, Ferguson JM, Dizon MP, Huhmann L, Kim DY, Do N, Brophy MT, Osborne TF, Spence AC, Fillmore NR, Swetter SM, Hartman RI. Area Deprivation Index and Melanoma Thickness in Veterans. JAMA Dermatol. 2025 Jun 01; 161(6):582-588.

View in: PubMed
Quinn RM, Bernal AM, Oh SY, Anampa JD. Trends in Incidence of Invasive Lobular Carcinoma of the Breast by Race: Patterns by Age, Cancer Stage, and Socioeconomic Factors in the United States, 1992-2019. Clin Breast Cancer. 2025 Jun; 25(4):e394-e402.e8.

View in: PubMed
Romatoski KS, Chung SH, Sawhney V, Papageorge MV, de Geus SWL, Ng SC, Kenzik K, Tseng JF, Sachs TE. Factors Associated With Surgical Management in Gallbladder Cancer-A Surveillance, Epidemiology, and End Results Medicare-Based Study. J Surg Res. 2024 Dec; 304:9-18.

View in: PubMed
Bauer PS, Gamboa AC, Otegbeye EE, Chapman WC, Rivard S, Regenbogen S, Hrebinko KA, Holder-Murray J, Wiseman JT, Ejaz A, Edwards-Hollingsworth K, Hawkins AT, Hunt SR, Balch GC, Wise PE. Short-Course TNT Improves Rectal Tumor Downstaging in a Retrospective Study of the US Rectal Cancer Consortium. J Surg Oncol. 2025 Mar; 131(3):498-506.

View in: PubMed
Shatsky RA, Trivedi MS, Yau C, Nanda R, Rugo HS, Davidian M, Tsiatis B, Wallace AM, Chien AJ, Stringer-Reasor E, Boughey JC, Omene C, Rozenblit M, Kalinsky K, Elias AD, Vaklavas C, Beckwith H, Williams N, Arora M, Nangia C, Roussos Torres ET, Thomas B, Albain KS, Clark AS, Falkson C, Hershman DL, Isaacs C, Thomas A, Tseng J, Sanford A, Yeung K, Boles S, Chen YY, Huppert L, Jahan N, Parker C, Giridhar K, Howard FM, Blackwood MM, Sanft T, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Symmans WF, Price E, Heditsian D, LeStage B, Perlmutter J, Pohlmann P, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.

View in: PubMed
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.

View in: PubMed
Dahl DM, Rodgers JP, Shipley WU, Michaelson MD, Wu CL, Parker W, Jani AB, Cury FL, Hudes RS, Michalski JM, Hartford AC, Song D, Citrin DE, Karrison TG, Sandler HM, Feng FY, Efstathiou JA. Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926. J Clin Oncol. 2024 Dec; 42(34):4095-4102.

View in: PubMed

People

Explore

Similar Concepts

Top Journals